138 related articles for article (PubMed ID: 7182456)
1. Pharmacokinetics of the pivaloyloxyethyl (POE) ester of methyldopa, a new prodrug of methyldopa.
Dobrinska MR; Kukovetz W; Beubler E; Leidy HL; Gomez HJ; Demetriades J; Bolognese JA
J Pharmacokinet Biopharm; 1982 Dec; 10(6):587-600. PubMed ID: 7182456
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of methyldopa in man after oral administration of the pivaloyloxyethyl ester.
Vickers S; Duncan CA; Ramjit HG; Dobrinska MR; Dollery CT; Gomez HJ; Leidy HL; Vincek WC
Drug Metab Dispos; 1984; 12(2):242-6. PubMed ID: 6144491
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of methyldopa in man.
Kwan KC; Foltz EL; Breault GO; Baer JE; Totaro JA
J Pharmacol Exp Ther; 1976 Aug; 198(2):264-77. PubMed ID: 781212
[TBL] [Abstract][Full Text] [Related]
4. Sensitive high-performance liquid chromatographic assay using electrochemical detection for a novel prodrug ester of methyldopa, pivaloyloxyethyl 3-(3,4-dihydroxyphenyl)-2-methylalaninate, in plasma and urine.
Musson DG; Vincek WC; Dobrinska MR; Vickers S; Leidy HL
J Chromatogr; 1984 Jun; 308():251-9. PubMed ID: 6746818
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentration of alpha-methyldopa and sulphate conjugate after oral administration of methyldopa and intravenous administration of methyldopa and methyldopa hydrochloride ethyl ester.
Saavedra JA; Reid JL; Jordan W; Rawlins MD; Dollery CT
Eur J Clin Pharmacol; 1975 Aug; 8(6):381-6. PubMed ID: 1233238
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of succinimidoethyl and pivaloyloxyethyl esters as progenitors of methyldopa in man, rhesus monkey, dog, and rat.
Vickers S; Duncan CA; White SD; Breault GO; Royds RB; de Schepper PJ; Tempero KF
Drug Metab Dispos; 1978; 6(6):640-6. PubMed ID: 33026
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of alpha-methyldopa in dogs.
Kochak GM; Mason WD
J Pharmacokinet Biopharm; 1985 Aug; 13(4):405-23. PubMed ID: 3841366
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects.
Skerjanec A; Campbell NR; Robertson S; Tam YK
J Clin Pharmacol; 1995 Mar; 35(3):275-80. PubMed ID: 7608316
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of methyldopa.
Myhre E; Rugstad HE; Hansen T
Clin Pharmacokinet; 1982; 7(3):221-33. PubMed ID: 7047042
[TBL] [Abstract][Full Text] [Related]
10. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Crevoisier C; Monreal A; Metzger B; Nilsen T
Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antihypertensive activity of some ester progenitors of methyldopa.
Saari WS; Freedman MB; Hartman RD; King SW; Raab AW; Randall WC; Engelhardt EL; Hirschmann R; Rosegay A; Ludden CT; Scriabine A
J Med Chem; 1978 Aug; 21(8):746-53. PubMed ID: 691000
[TBL] [Abstract][Full Text] [Related]
12. Sulfate and methyldopa metabolism: metabolite patterns and platelet phenol sulfotransferase activity.
Campbell NR; Sundaram RS; Werness PG; Van Loon J; Weinshilboum RM
Clin Pharmacol Ther; 1985 Mar; 37(3):308-15. PubMed ID: 3855724
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and absolute bioavailability of diltiazem in humans.
Ochs HR; Knüchel M
Klin Wochenschr; 1984 Apr; 62(7):303-6. PubMed ID: 6727272
[TBL] [Abstract][Full Text] [Related]
14. The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man.
Clements JA; Critchley JA; Prescott LF
Br J Clin Pharmacol; 1984 Oct; 18(4):481-5. PubMed ID: 6487489
[TBL] [Abstract][Full Text] [Related]
15. Intestinal absorption studies on peptide mimetic alpha-methyldopa prodrugs.
Wang HP; Lu HH; Lee JS; Cheng CY; Mah JR; Ku CY; Hsu W; Yen CF; Lin CJ; Kuo HS
J Pharm Pharmacol; 1996 Mar; 48(3):270-6. PubMed ID: 8737052
[TBL] [Abstract][Full Text] [Related]
16. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
17. Influence of route of administration on the pharmacokinetics of methylprednisolone.
Antal EJ; Wright CE; Gillespie WR; Albert KS
J Pharmacokinet Biopharm; 1983 Dec; 11(6):561-76. PubMed ID: 6678310
[TBL] [Abstract][Full Text] [Related]
18. Absorption, metabolism and distribution of (14C)-O-methyldopa and (14C)-L-dopa after oral administration to rats.
Rivera-Calimlim L
Br J Pharmacol; 1974 Feb; 50(2):259-63. PubMed ID: 4425764
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and bioavailability of metergoline in healthy volunteers after single i.v. and oral administration.
Martini A; Moro E; Marrari P; Pacciarini MA; Sega R; Dell'Osso L; Bertelli A; Tamassia V
Int J Clin Pharmacol Res; 1983; 3(1):27-34. PubMed ID: 6679505
[TBL] [Abstract][Full Text] [Related]
20. The absorption and conjugation of methyldopa in patients with coeliac and Crohn's diseases during treatment.
Renwick AG; Higgins V; Powers K; Smith CL; George CF
Br J Clin Pharmacol; 1983 Jul; 16(1):77-83. PubMed ID: 6882626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
